https://www.selleckchem.com/JAK.html
8 months (range from 5.6 to 24.4), 10.1 months (range from 6.4 to 13.2), 8.7 months (range from 4.7 to 15.2) and 6.0 months (range from 2.9 to 8. for Pazopanib, Axitinib, Cabozantinib, Sunitinib, respectively, after first-line IO. Pazopanib results in the longest weighted median PFS, after previous IO-failure, regardless of treatment line, as well as in specific second-line, post-first-line IO failure settings. Pending novel studies, Pazopanib appears to represent the most promising treatment option after prior IO. Pazopanib results in the longest
Like
Comment
Share
